Investigational Drug Information for Imagabalin
✉ Email this page to a colleague
What is the drug development status for Imagabalin?
Imagabalin is an investigational drug.
There have been 10 clinical trials for Imagabalin.
The most recent clinical trial was a Phase 3 trial, which was initiated on October 1st 2007.
The most common disease conditions in clinical trials are Anxiety Disorders, Disease, and Renal Insufficiency. The leading clinical trial sponsors are Pfizer and [disabled in preview].
Summary for Imagabalin
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 318 |
| WIPO Patent Applications | 189 |
| Japanese Patent Applications | 109 |
| Clinical Trial Progress | Phase 3 (2007-10-01) |
| Vendors | 19 |
Recent Clinical Trials for Imagabalin
| Title | Sponsor | Phase |
|---|---|---|
| A Phase 1 Study To Estimate The Effects Of PD 0332334 On Lithium Pharmacokinetics In Healthy Subjects | Pfizer | Phase 1 |
| Evaluating The Effects Of Cimetidine On The Elimination Of PD 0332334 From The Body | Pfizer | Phase 1 |
| Investigation Of How PD 0332334 And Metformin Are Eliminated From The Body When They Are Administered At The Same Time | Pfizer | Phase 1 |
Clinical Trial Summary for Imagabalin
Top disease conditions for Imagabalin
Top clinical trial sponsors for Imagabalin
US Patents for Imagabalin
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
